Cadrenal Therapeutics, Inc. (CVKD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.00
- As of
Kresmion compiles this page from CVKD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cadrenal Therapeutics, Inc. (CVKD): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-07.
See the full CVKD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CVKD on one page. Preview it with sample data, then open it live with a free account.
Preview the CVKD dossierActive signals for CVKD
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 21.3%, EPS $-1.14 vs $-1.4484 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 14.8% - EPS $-1.87 vs $-1.6286 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 15.9% - EPS $-1.31 vs $-1.5572 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 20.3% - EPS $-1.43 vs $-1.1883 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 37.1% - EPS $-1.04 vs $-1.6524 estimate
FREE, NO ACCOUNT
Every signal on CVKD, as it fires
New filings, 13F moves and cross asset signals on CVKD land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, CVKD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CVKD against its peers
CVKD's return on equity of -483.3% ranks in the 31st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | CVKD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 131000 | n/a | 11 |
| Gross margin | n/a | 58.1% | n/a | 8 |
| Operating margin | n/a | -5143.5% | n/a | 10 |
| Net margin | n/a | -4911.4% | n/a | 10 |
| Return on equity | -483.3% | -212.7% | 31 | 17 |
| 1 year | -92.9% | -93.9% | 58 | 12 |
Peers (19): ONCO, SXTP, MBIO, HCWB, APVO, REVB, JUNS, BRTX, PPCB, CLDI, ADTX, MTNB, VIVS, SILO, GOVX, ERNA, GRI, PMCB, PCSA. Left out: MLEC (period gap), XRTX (no annual filing), NYMXF (period gap), VCNX (period gap), LSBCF (period gap), VRAX (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CVKD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CVKD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CVKD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.